For the reader, it is helpful to appreciate the precarious position that PMRT has held in treatment paradigms. Early trials, such as the DBCG 82 b&c trials, included patients with one or more positive axillary nodes and showed improved local control as well as improved survival. 4, 5 Questions regarding the adequacy of surgery and older systemic agents used in these trials make many clinicians wary about applying historic results to modern-day patients.
By the late 1990s a consensus report was released stating that insufficient evidence exists to make evidencebased recommendations regarding PMRT in patients with small tumors and 1-3 positive axillary lymph nodes. 6, 7 More recently, the treatment pendulum has been swinging back with the results of the Early Breast Cancer Trialist's Collaborative Group meta-analysis, reporting reduction of locoregional recurrence (LRR) and improvement in breast cancer mortality for this patient population. 2 In the absence of clear, randomized data, oncologists are forced to weigh clinicopathologic risk factors, ultimately relying on their clinical judgment to recommend or not recommend PMRT in patients with small primary tumors (T1-T2) and 1-3 positive lymph nodes. While tallying up an individual patient's risk factors for local recurrence, lymphovascular invasion, tumor size, nodal involvement, extracapsular extension, age, etc., I cannot help but reflect on my medical oncology colleagues. They too were once weighing clinical and pathologic risk factors down to the millimeter, using actuarial science to treat individual patients with biologically heterogeneous tumors. 8, 9 That is until the 21-gene recurrence score became widely available, allowing medical oncologists to tailor systemic therapy recommendations for estrogen receptor (ER)-positive, HER2-negative breast cancer patients by integrating their individual molecular profiles. 10, 11 Although systemic management of early-stage breast cancer patients has moved forward into a genomic era, local therapies such as radiation and surgery continue to treat cancer empirically. In the current issue of Annals of Surgical Oncology, the article entitled ''21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients'' 3 attempts to clarify if there is a relationship between the 21-gene recurrence score and local recurrence. The authors retrospectively reviewed records of stages I and II, ER-positive breast cancer patients who were treated with breast-conserving therapy (BCT) or mastectomy alone. Patients received systemic therapy based upon their 21-gene recurrence score. The study was limited by rather marked differences in patient and tumor characteristics for each local control group. Most notably, there was a statistically significant difference in patient age, stage, and lymph node status between the BCT and mastectomy-alone groups. Additionally, there was a very low event rate in the study, with only 11 LRRs in the entire cohort. As the authors of this paper highlighted, a low local recurrence rate is expected in stages I and II breast cancer patients. Despite these limitations, a relationship was identified between recurrence score and mastectomy-alone patients. An association between recurrence score and LRR has been examined in two prior retrospective analyses. 12, 13 The retrospective analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 and B-20 trials evaluated ER positive, node-negative breast cancer patients enrolled in these two trials. 12 In NSABP B-14, participants were randomized to 5 years of placebo versus tamoxifen; local therapy could have been either BCT or mastectomy without radiation therapy.
14 NSABP-B20 was a prospective randomized trial with three arms that randomly assigned patients to tamoxifen alone or tamoxifen with one of two systemic therapy regimens. 15 The authors of the NSABP-14 and NSABP-20 retrospective review concluded that recurrence score had a significant association with the risk of local and regional recurrence. 12 There were some unusual findings that suggested radiation may be more effective in patients with higher recurrence scores. Jegadeesh and colleagues 3 took note that in the NSABP B-14 and B-20 review, a high recurrence score predicted for LRR in all mastectomy-alone patients, while recurrence score did not predict for LRR in breast-conservation patients over the age of 50 years. They felt that this further substantiated their hypothesis that radiotherapy may in some way nullify the LRR implications of a high recurrence score. This hypothesis was further supported by a second and more recent retrospective review of the EORTC E2197 trial. 13 This trial evaluated the recurrence score in ER-positive, node-positive patients, all of whom received BCT. Interestingly, no association between recurrence score and risk of local recurrence was identified.
I would like to commend the authors of this article for utilizing recurrence scores in a less traditional way. Rather than adopting the original systemic therapy stratification system of RS \ 18, RS 18-30, and RS C 31 as low, intermediate, and high risk, respectively, they correlated locoregional outcomes to recurrence scores to mathematically find the most significant relationship. This is an approach that is reasonable in that the threshold for scores for risk of local recurrence may not mirror thresholds for systemic recurrence.
''The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients'' retrospective review provides fodder for future prospective trials, advancing the dialogue regarding local therapy and asking how we can better select treatments for individuals with cancer.
